Literature DB >> 20160856

Reactions of Trimethylsilyl Fluorosulfonyldifluoroacetate with Purine and Pyrimidine Nucleosides.

Magdalena Rapp1, Xiaohong Cai, Wei Xu, William R Dolbier, Stanislaw F Wnuk.   

Abstract

Difluorocarbene, generated from trimethylsilyl fluorosulfonyldifluoroacetate (TFDA), reacts with the uridine and adenosine substrates preferentially at the enolizable amide moiety of the uracil ring and the 6-amino group of the purine ring. 2',3'-Di-O-acetyl-3'-deoxy-3'-methyleneuridine reacts with TFDA to produce 4-O-difluoromethyl product derived from an insertion of difluorocarbene into the 4-hydroxyl group of the enolizable uracil ring. Reaction of the difluorocarbene with the adenosine substrates having the unprotected 6-amino group in the purine ring produced the 6-N-difluoromethyl derivative, while reaction with 6-N-benzoyl protected adenosine analogues gave the difluoromethyl ether product derived from the insertion of difluorocarbene into the enol form of the 6-benzamido group. Treatment of the 6-N-phthaloyl protected adenosine analogues with TFDA resulted in the unexpected one-pot conversion of the imidazole ring of the purine into the corresponding N-difluoromethylthiourea derivatives. Treatment of the suitably protected pyrimidine and purine nucleosides bearing an exomethylene group at carbons 2', 3' or 4' of the sugar rings with TFDA afforded the corresponding spirodifluorocyclopropyl analogues but in low yields.

Entities:  

Year:  2009        PMID: 20160856      PMCID: PMC2663956          DOI: 10.1016/j.jfluchem.2008.12.004

Source DB:  PubMed          Journal:  J Fluor Chem        ISSN: 0022-1139            Impact factor:   2.050


  21 in total

1.  Spirocyclic restriction of nucleosides. Synthesis of the first exemplary syn-1-oxaspiro[4.4]nonanyl member.

Authors:  L A Paquette; R T Bibart; C K Seekamp; A L Kahane
Journal:  Org Lett       Date:  2001-12-13       Impact factor: 6.005

2.  Carbon-13 magnetic resonance. XXVI. A quantitative determination of the tautomeric populations of certain purines.

Authors:  M T Chenon; R J Pugmire; D M Grant; R P Panzica; L B Townsend
Journal:  J Am Chem Soc       Date:  1975-08-06       Impact factor: 15.419

3.  Synthesis of the phosphoramidite derivatives of 2'-deoxy-2'-C-alpha-methylcytidine and 2'-deoxy-2'-C-alpha-hydroxymethylcytidine: analogues for chemical dissection of RNA's 2'-hydroxyl group.

Authors:  Nan-Sheng Li; Joseph A Piccirilli
Journal:  J Org Chem       Date:  2004-07-09       Impact factor: 4.354

4.  Addition of difluorocarbene to 3',4'-unsaturated nucleosides: synthesis of 2'-deoxy analogues with a 2-oxabicyclo[3.1.0]hexane framework.

Authors:  Ireneusz Nowak; John F Cannon; Morris J Robins
Journal:  J Org Chem       Date:  2007-01-19       Impact factor: 4.354

Review 5.  Pharmacological breast cancer therapy (review).

Authors:  Patrick M Navolanic; James A McCubrey
Journal:  Int J Oncol       Date:  2005-11       Impact factor: 5.650

Review 6.  Thymidylate synthase inhibitors.

Authors:  P V Danenberg; H Malli; S Swenson
Journal:  Semin Oncol       Date:  1999-12       Impact factor: 4.929

7.  Addition of difluorocarbene to 4',5'-unsaturated nucleosides: synthesis and deoxygenation reactions of difluorospirocyclopropane nucleosides.

Authors:  Ireneusz Nowak; Morris J Robins
Journal:  J Org Chem       Date:  2006-11-10       Impact factor: 4.354

8.  Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.

Authors:  E M Acton; R N Goerner; H S Uh; K J Ryan; D W Henry; C E Cass; G A LePage
Journal:  J Med Chem       Date:  1979-05       Impact factor: 7.446

9.  Synthesis of spirocycles via ring closing metathesis of heterocycles carrying gem-diallyl substituents obtained via ring opening of (halomethyl)cyclopropanes with allyltributyltin.

Authors:  Mukund K Gurjar; Somu V Ravindranadh; Kuppusamy Sankar; Sukhen Karmakar; Joseph Cherian; Mukund S Chorghade
Journal:  Org Biomol Chem       Date:  2003-04-21       Impact factor: 3.876

Review 10.  Gemcitabine (Gemzar) in non-small cell lung cancer.

Authors:  Christian Manegold
Journal:  Expert Rev Anticancer Ther       Date:  2004-06       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.